NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
NovaBridge presented mature Phase 1b data for givastomig at ESMO 2026, showing a 79% objective response rate and 16.9-month median progression-free survival at the selected 8 mg/kg dose in first-line metastatic gastroesophageal adenocarcinoma. Efficacy held across CLDN18.2 expression levels, including a 75% response rate in patients with 1-74% expression who are ineligible for currently approved CLDN18.2-targeted therapies, with no Grade 4 or 5 treatment-related adverse events attributed to the drug. The company has aligned with the FDA on a global registrational study protocol and holds Orphan Drug and Fast Track designations; an investor webcast is set for November 2, 2026.
Key figures
- Drug Name
- givastomig (TJ033721 / ABL111)
- Phase Of Trial
- Phase 1b (advancing to registrational Phase 3)
- Selected dose
- 8 mg/kg
- Median pfs months
- 16.9
- Patients enrolled
- 71
- Disease control rate
- 97% (28/29)
- Orr cldn18 2 ge 75pct
- 82%
- Median follow up months
- 17.8
- Objective response rate
- 79% (23/29) at 8 mg/kg
- Orr cldn18 2 1 to 74pct
- 75%
- Median duration of response months
- 15.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.